Drug Profile

AVE 5883

Alternative Names: AVE-5883

Latest Information Update: 17 Mar 2009

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aventis Pharmaceuticals
Class Antiasthmatics
Mechanism of Action Neurokinin 1 receptor antagonists; Neurokinin 2 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Asthma

Most Recent Events

20 Jun 2006 Data presented at the 102nd International Conference of the American Thoracic Society (ATS-2006) have been added to the Obstructive Airways Disease therapeutic trials section
29 Sep 2004 Phase-I/II clinical trials in Asthma in France (Inhalation)
29 Sep 2004 Phase-I/II clinical trials in Asthma in Netherlands (Inhalation)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com